Progenics Pharma (PGNX) Reports Q4 Loss of $0.10/Share
Tweet
Share
E-mailGet Alerts PGNX Hot Sheet
Price: $4.10 --0%
Financial Fact:
Operating income (loss): 36.2M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Operating income (loss): 36.2M
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Progenics Pharma (NASDAQ: PGNX) reported Q4 EPS of ($0.10), versus ($0.10) reported last year. Revenue for the quarter came in at $4.65 million, versus $5.1 million reported last year.
For earnings history and earnings-related data on Progenics Pharma (PGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
- Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
- Movano (MOVE) Misses Q2 EPS by 195c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
